Thông tin cho nhân viên y tế
Thuốc mới và thông tin từ Drugs.com
- November 26, 2025 — Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announce the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Voyxact…
- 25 November 2025 — AstraZeneca’s Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) has been approved in the US for the treatment of adult patients with…
- EAST HANOVER, N.J., Nov. 24, 2025 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of children two years and older, teens, and adults l…
- RAHWAY, N.J.–(BUSINESS WIRE) November 21, 2025 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) and Keytruda…
- RALEIGH, N.C., Nov. 20, 2025 /PRNewswire/ — Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug…
- RALEIGH, N.C., Nov. 20, 2025 /PRNewswire/ — Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on development of oncology, immunology, and critical care therapies, announced today the U.S. Food and Drug…
- WEDNESDAY, Nov. 26, 2025 — Less than 20 percent of screening-eligible individuals undergo lung cancer screening (LCS), according to a research letter published online Nov. 19 in the Journal of the American Medical Association. Priti Bandi, Ph.D…
- WEDNESDAY, Nov. 26, 2025 — Women with persistent thyroid hormone imbalance across pregnancy may have an increased risk of having children with autism spectrum disorder (ASD), according to a study published online Nov. 25 in the Journal of Clinical…
- WEDNESDAY, Nov. 26, 2025 — Trajectories of long COVID have been identified, according to a study published online Nov. 17 in Nature Communications. Tanayott Thaweethai, Ph.D., from Massachusetts General Hospital Biostatistics in Boston, and…
- WEDNESDAY, Nov. 26, 2025 — Grant funding disruptions affected about one in 30 trials, according to a research letter published online Nov. 17 in JAMA Internal Medicine. Vishal R. Patel, M.D., M.P.H., from Harvard Medical School in Boston, and…
- WEDNESDAY, Nov. 26, 2025 — Routine first-trimester ultrasounds lead to earlier detection of fetal anomalies, according to a study published online Nov. 25 in PLOS Medicine. Jehan N. Karim, from the University of Oxford in the United Kingdom, and…
- WEDNESDAY, Nov. 26, 2025 — Obstructive sleep apnea (OSA) seems to be an independent risk factor for development of Parkinson disease, and early use of continuous positive airway pressure (CPAP) could modify the risk, according to a study published…
Thông tin từ The Pharma Letter
- California, USA-based biotech Vera Therapeutics has announced the submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) through the Accelerated Approval Program for atacicept as a treatment of adults with immunoglobulin A nephropathy (IgAN).
- Spanish plasma-derived medicines company Grifols today announced the appointment of Tomás Dagá, Grifols’ board member, as vice president of the board of Grifols Egypt for Plasma Derivatives (GEPD), the joint venture created together with the Government of Egypt to deploy the country’s first comprehensive plasma ecosystem, and the first in Africa and the Middle East.
- Japanese drug developer Renalys Pharma yesterday announced positive top-line results from its Phase III clinical study of sparsentan (development code: RE-021), an orally administered dual endothelin and angiotensin II receptor antagonist (DEARA), in Japanese patients with IgA nephropathy (IgAN).
- The global market for intratumoral cancer therapies is set for a long growth runway, according to new sector analysis from DataM Intelligence, outlining rising clinical use of oncolytic viruses, adenoviral vectors, and localized immunomodulators.
- Danish drugmaker Novo Nordisk has asked the US Food and Drug Administration regulator to assess a stronger 7.2 mg version of its obesity drug Wegovy (semaglutide) under the Commissioner's national priority voucher scheme, potentially clearing the way for a rapid decision. The filing targets adults needing chronic weight-management support.
- US biotech Lunai Bioworks has signed its first letter of intent to license its off-the-shelf immune cell therapy after reporting complete tumor regression in preclinical pancreatic-cancer models.
Thông tin từ BioPharmaDive
- The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.
- In a rapidly heating market, Otsuka is the first to secure FDA clearance for an "anti-APRIL" therapy targeting IgA nephropathy.
- The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends restraints over more medicines.
- Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor function.
- The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a Sprint Bioscience drug targeting “TREX1.”
- Top executives can steer large pharma companies in many ways. Here are the ones who employees approve of the most.
Thông tin từ STAT News
- On Tuesday, the Trump administration celebrated drug price cuts it had secured through a Democrat-created program — despite Republicans’ longstanding antipathy of the policy.
- In this edition of AI Prognosis: Patients are at the heart of health care, and yet, they're rarely part of conversations around AI in health care.
- And more biotech news brought to you by The Readout
- And other health news stories from the Morning Rounds newsletter
- The Trump administration unveiled the prices for 15 drugs that were the subject of Medicare negotiations for the second year
- Opinion: Why my colleagues and I are undertaking an independent review of the hepatitis B birth dose“The Vaccine Integrity Project’s evidence review of the first dose of the hepatitis B vaccine will offer a transparent, data-driven view of its safety and effectiveness,” Michael Osterholm writes.
Thông tin từ Nature Review Drug Discovery
- Nature Reviews Drug Discovery, Published online: 26 November 2025; doi:10.1038/d41573-025-00193-wNovel antimalarial passes key phase III test
- Nature Reviews Drug Discovery, Published online: 25 November 2025; doi:10.1038/d41573-025-00196-7Repairing spinal cord damage
- Nature Reviews Drug Discovery, Published online: 25 November 2025; doi:10.1038/d41573-025-00195-8Enhancing RNA stability
- Nature Reviews Drug Discovery, Published online: 25 November 2025; doi:10.1038/d41573-025-00197-6Designing G-protein-selective allosteric modulators
- Nature Reviews Drug Discovery, Published online: 25 November 2025; doi:10.1038/d41573-025-00194-9A broad-spectrum snakebite antivenom
- Nature Reviews Drug Discovery, Published online: 24 November 2025; doi:10.1038/s41573-025-01323-0Epigenetic editing has emerged as a powerful hit-and-run approach to precise modification of gene expression without altering the underlying DNA sequence. This Review explores the therapeutic potential of epigenetic editing, highlights tools and concepts, assesses challenges and considerations, discusses in vivo studies and examines approaches and […]